Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of antidiabetic drugs on the gut-microbiota of T2D patients
ChiCTR-OPC-17010757Phase 4Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Mar 2017
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of acarbose in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Xinqiao Hospital. Primary endpoints: Glucose, Gut microbiota composition and 1 more. Started Mar 2017; status: recruiting.
02
Drugs
acarbose
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-OPC-17010757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17010757.